mTOR inhibitors, including temsirolimus (which is approved for relapse/refractory MCL in European countries), ridaforolimus, and everolimus impart their therapeutic benefit by inhibiting mTORC1 via allosterical binding. Here, MTOR is linked to mantle cell lymphoma.